JP2023535483A5 - - Google Patents
Info
- Publication number
- JP2023535483A5 JP2023535483A5 JP2023505841A JP2023505841A JP2023535483A5 JP 2023535483 A5 JP2023535483 A5 JP 2023535483A5 JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023535483 A5 JP2023535483 A5 JP 2023535483A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- use according
- disease
- tmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059047P | 2020-07-30 | 2020-07-30 | |
| US63/059,047 | 2020-07-30 | ||
| US202063131120P | 2020-12-28 | 2020-12-28 | |
| US63/131,120 | 2020-12-28 | ||
| PCT/IB2021/056971 WO2022024062A1 (en) | 2020-07-30 | 2021-07-30 | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535483A JP2023535483A (ja) | 2023-08-17 |
| JP2023535483A5 true JP2023535483A5 (https=) | 2024-08-06 |
Family
ID=77265125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505841A Pending JP2023535483A (ja) | 2020-07-30 | 2021-07-30 | 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230372313A1 (https=) |
| EP (1) | EP4188381A1 (https=) |
| JP (1) | JP2023535483A (https=) |
| KR (1) | KR20230047146A (https=) |
| CN (1) | CN116322679A (https=) |
| AU (1) | AU2021317180A1 (https=) |
| BR (1) | BR112023001362A2 (https=) |
| CA (1) | CA3187086A1 (https=) |
| IL (1) | IL300096A (https=) |
| MX (1) | MX2023001285A (https=) |
| WO (1) | WO2022024062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| KR20260021150A (ko) | 2024-08-05 | 2026-02-13 | 충북대학교 산학협력단 | Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10617713B2 (en) * | 2016-03-08 | 2020-04-14 | Neurocentria, Inc. | Methods of modifying neuronal function by changing intracellular magnesium levels |
| EP3452045A1 (en) * | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
-
2021
- 2021-07-30 US US18/007,433 patent/US20230372313A1/en active Pending
- 2021-07-30 CA CA3187086A patent/CA3187086A1/en active Pending
- 2021-07-30 EP EP21752208.5A patent/EP4188381A1/en active Pending
- 2021-07-30 WO PCT/IB2021/056971 patent/WO2022024062A1/en not_active Ceased
- 2021-07-30 BR BR112023001362A patent/BR112023001362A2/pt unknown
- 2021-07-30 CN CN202180065014.XA patent/CN116322679A/zh active Pending
- 2021-07-30 AU AU2021317180A patent/AU2021317180A1/en active Pending
- 2021-07-30 MX MX2023001285A patent/MX2023001285A/es unknown
- 2021-07-30 JP JP2023505841A patent/JP2023535483A/ja active Pending
- 2021-07-30 KR KR1020237007140A patent/KR20230047146A/ko active Pending
- 2021-07-30 IL IL300096A patent/IL300096A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415788A1 (en) | Ocular treatments for neurological and neuropsychiatric disorders | |
| US8008285B2 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia | |
| TWI494293B (zh) | 用於治療認知障礙之α-胺基醯胺衍生物 | |
| US8383681B2 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders | |
| US11590107B2 (en) | Methods for treating neurological disorders with α1A-AR partial agonists | |
| JP2023535483A5 (https=) | ||
| JPH0422889B2 (https=) | ||
| JP2023512366A5 (https=) | ||
| JP2012197304A (ja) | ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用 | |
| JP2022519274A5 (https=) | ||
| JP2022520747A5 (https=) | ||
| WO2022104383A1 (en) | Pharmacological agents for treating conditions of the eye | |
| ES3004543T3 (en) | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders | |
| KR20130113430A (ko) | 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제 | |
| JP4739760B2 (ja) | バルビツール酸誘導体を使用する運動障害の治療方法 | |
| JP7337081B2 (ja) | レストレスレッグズ症候群を治療するための治療薬 | |
| CA3187086A1 (en) | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same | |
| JP7086076B2 (ja) | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP3494651B2 (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| Nakanishi et al. | Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs | |
| JP2023082771A (ja) | パーキンソン病治療薬 | |
| US20240252579A1 (en) | Use of cns-homing targeting peptides for treating neurological disorders | |
| JP2009508926A (ja) | 神経変性疾患の治療のための２−アミノアルコール | |
| JP2003226642A (ja) | 眼疾患予防及び／又は治療薬 | |
| Zúñiga-Ramírez et al. | Preladenant, adenosine A |